Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6334

Provisional Schedule

Committee meeting 03 September 2024
Expected publication 13 November 2024

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ

Stakeholders

Companies sponsors Takeda UK (brentuximab vedotin)
Others Department of Health and Social Care
  NHS England
Patient carer groups African Caribbean Leukaemia Trust
  Anthony Nolan
  Black Health Agency for Equality
  Blood Cancer UK
  Cancer Black Care
  Cancer Equality
  Cancer52
  DKMS
  Follicular Lymphoma Foundation
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Leukaemia Cancer Society
  Leukaemia Care
  Lymphoma Action
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  WMUK
Professional groups Association of Cancer Physicians
  British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Institute of Radiology
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Society for Haematology
  British Transplantation Society
  Cancer Research UK
  NHS Blood and Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
  United Kingdom Cutaneous Lymphoma Group
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Accord Healthcare Limited (doxorubicin)
  Hospira (vinblastine)
  Janssen-Cilag Ltd (doxorubicin)
  Kyowa Kirin Ltd (bleomycin)
  Medac GmbH (dacarbazine, doxorubicin)
  Pfizer Limited (doxorubicin)
  Seacross Pharmaceuticals Ltd (doxorubicin)
  Teva Pharma B.V. (doxorubicin)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Haematological Malignancies Group
  Cochrane UK
  Genomics England
  Institute of Cancer Research
  Leukaemia Busters
  Leukaemia UK
  Lymphoma Research Trust
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
02 February 2024 Invitation to participate
29 November 2023 - 09 January 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 November 2023 In progress. Appraisal in progress.
06 October 2023 For information, please see draft timelines. This evaluation is expected to start during late November 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the evaluation during early-February 2024. Please note this evaluation will include a review of TA594 which originally published in August 2019.
11 September 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
11 September 2023 Topic selection
22 August 2023 This evaluation will include a review of TA594 published August 2019
20 July 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual